BeStock  
Stocks › Biotechnology › CLDX

Celldex Therapeutics CLDX

US equityMarket cap rank #2636Biotechnology
$27.42 −$0.54 (-1.93%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.40 -0.07%
Open$27.01
Prev close$27.96
Day range$26.64 – $28.43
Volume1.72M
Market cap$2.15B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$82.25M-11.7% YoY
Net profit-$75.56M-12.7% YoY
Diluted EPS-$0.96+5.0% YoY
Free cash flow-$66.70M-35.9% YoY
Operating cash flow-$65.04M

Revenue, last 8 quarters

$1.2MDec '24$695.0KMar '25$730.0KJun '25$0.0Sep '25$121.0KDec '25$15.0KMar '26$22.0KJun '26$0.0Sep '26

Net profit, last 8 quarters

$-47.1MDec '24$-53.8MMar '25$-56.6MJun '25$-67.0MSep '25$-81.3MDec '25$-78.7MMar '26$-73.5MJun '26$-75.6MSep '26

Diluted EPS by quarter

-0.71Dec '24-0.81Mar '25-0.85Jun '25-1.01Sep '25-1.22Dec '25-1.18Mar '26-0.94Jun '26-0.96Sep '26

Free cash flow by quarter

$-33.2MDec '24$-54.6MMar '25$-44.7MJun '25$-49.1MSep '25$-65.2MDec '25$-67.2MMar '26$-60.6MJun '26$-66.7MSep '26

Annual revenue

$7.4MFY20$4.7MFY21$2.4MFY22$6.9MFY23$7.0MFY24$1.5MFY25

Profitability & balance sheet

Operating margin-211,684.8%
Net margin-195,608.9%
Return on equity-49.5%
Return on assets-45.1%
Return on invested capital-49.0%
Current ratio10.97
Liabilities / assets10.0%
Cash & investments$650.32M
Total debt$8.43M
Net cash (debt)$641.89M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $0.00 $22,000.00 $15,000.00 $1.55M $121,000.00
Total Operating Revenue $0.00 $22,000.00 $15,000.00 $1.55M $121,000.00
Operating Expense $82.25M $80.65M $84.45M $288.91M $87.27M
Selling and Admin Expenses $14.84M $13.10M $11.45M $43.84M $11.94M
-General & Admin Expense $14.84M $13.10M $11.45M $43.84M $11.94M
Research & Development $67.41M $67.54M $73.00M $245.07M $75.33M
Operating Profit -$82.25M -$80.62M -$84.44M -$287.37M -$87.15M
Other Income (Expense) $6.69M $7.12M $5.75M $28.61M $5.84M
Gain on Sale of Security $6.69M $7.12M $5.75M $28.61M $5.84M
Pretax Profit -$75.56M -$73.50M -$78.69M -$258.76M -$81.32M
Net Profit -$75.56M -$73.50M -$78.69M -$258.76M -$81.32M
Profit from Continuing Operations -$75.56M -$73.50M -$78.69M -$258.76M -$81.32M
Net Income to Parent Company -$75.56M -$73.50M -$78.69M -$258.76M -$81.32M
Net Income to Common Stockholders -$75.56M -$73.50M -$78.69M -$258.76M -$81.32M
Basic EPS -$0.96 -$0.94 -$1.18 -$3.90 -$1.22
Diluted EPS -$0.96 -$0.94 -$1.18 -$3.90 -$1.22
Special Income (Charges) – – – $0.00 –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $721.53M $782.35M $511.25M $582.98M $582.98M
Total Current Assets $663.74M $724.93M $459.22M $534.66M $534.66M
Cash and Cash Equivalents & Short-Term Investments $650.32M $717.59M $451.46M $518.57M $518.57M
-Cash and Cash Equivalents $26.95M $47.45M $35.73M $28.87M $28.87M
-Short Term Investments $623.37M $670.13M $415.73M $489.70M $489.70M
Receivables $355,000.00 $230,000.00 $230,000.00 $2.02M $2.02M
-Accounts Receivable $355,000.00 $230,000.00 $230,000.00 $2.02M $2.02M
Other Current Assets $13.06M $7.11M $7.53M $14.08M $14.08M
Total Non-Current Assets $57.80M $57.42M $52.03M $48.32M $48.32M
Net PPE $20.92M $14.79M $9.41M $7.77M $7.77M
-Gross PPE $20.92M $14.79M $9.41M $31.68M $31.68M
Non-Current Prepaid Assets $9.10M $14.80M $14.80M $13.36M $13.36M
Goodwill and Other Intangible Assets $27.19M $27.19M $27.19M $27.19M $27.19M
-Other Intangible Assets $27.19M $27.19M $27.19M $27.19M $27.19M
Other Non-Current Assets $586,000.00 $634,000.00 $634,000.00 – –
Total Liabilities $72.06M $67.79M $55.03M $55.82M $55.82M
Total Current Liabilities $60.52M $61.33M $51.47M $50.99M $50.99M
Payables $11.24M $14.68M $10.36M $1.18M $1.18M
-Accounts Payable $11.24M $14.68M $10.36M $1.18M $1.18M
Current Accrued Expenses $46.61M $43.86M $38.42M $47.03M $47.03M
Short-Term Debt and Capital Lease Obligation $1.44M $1.56M $1.47M $1.55M $1.55M
-Current Capital Lease Obligation $1.44M $1.56M $1.47M $1.55M $1.55M
Other Current Liabilities $1.23M $1.23M $1.23M $1.23M $1.23M
Total Non-Current Liabilities $11.55M $6.46M $3.56M $4.83M $4.83M
Long Term Debt and Capital Lease Obligation $8.43M $3.35M $443,000.00 $784,000.00 $784,000.00
-Long Term Capital Lease Obligation $8.43M $3.35M $443,000.00 $784,000.00 $784,000.00
Other Non-Current Liabilities $3.11M $3.11M $3.11M $4.04M $4.04M
Total Equity $649.47M $714.56M $456.23M $527.17M $527.17M
Stockholders' Equity $649.47M $714.56M $456.23M $527.17M $527.17M
Capital Stock $79,000.00 $79,000.00 $67,000.00 $67,000.00 $67,000.00
-Common Stock $79,000.00 $79,000.00 $67,000.00 $67,000.00 $67,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $2.69B $2.68B $2.35B $2.34B $2.34B
Retained Earnings -$2.04B -$1.97B -$1.89B -$1.81B -$1.81B
Gains/Losses Not Affecting Retained Earnings -$329,000.00 $1.30M $2.52M $3.63M $3.63M
-Accumulated Depreciation – – – -$23.90M -$23.90M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$65.04M -$57.41M -$65.59M -$210.95M -$63.94M
Net cash flow from continuing operations -$65.04M -$57.41M -$65.59M -$210.95M -$63.94M
Net Income from Continuing Operations -$75.56M -$73.50M -$78.69M -$258.76M -$81.32M
Gain/Loss from Continuing Operations $47,000.00 $1,000.00 $3,000.00 $12,000.00 $0.00
Depreciation & Depletion & Amortization $1.16M $902,000.00 $854,000.00 $3.38M $816,000.00
Change in Working Capital -$872,000.00 $8.48M $4.35M $14.06M $8.53M
-Change in Receivables -$125,000.00 $0.00 $1.79M -$1.32M -$1.93M
-Change in Prepaid Assets -$5.11M -$1.17M $6.28M $8.71M $8.47M
-Change in Payables and Accrued Expense -$823,000.00 $10.14M -$287,000.00 $11.03M $4.60M
-Change in Other Current Assets $5.75M $0.00 -$2.08M -$3.61M -$3.99M
-Change in Other Current Liabilities -$567,000.00 -$490,000.00 -$1.36M -$753,000.00 $1.38M
Net cash flow from investing $43.42M -$255.52M $72.12M $209.07M $55.43M
Net Cash Flow from Continuing Investing Activities $43.42M -$255.52M $72.12M $209.07M $55.43M
Net PPE Purchase and Sale -$1.67M -$3.18M -$1.64M -$2.71M -$1.28M
Net Investment Purchase and Sale $45.09M -$252.34M $73.76M $211.79M $56.71M
Financing Cash Flow $1.12M $324.66M $327,000.00 $2.39M $1.35M
Net Cash Flow from Continuing Financing Activities $1.12M $324.66M $327,000.00 $2.39M $1.35M
Net Common Stock Issuance $0.00 $323.83M $0.00 $0.00 $0.00
Proceeds from Stock Option Exercised $1.12M $825,000.00 $327,000.00 $2.39M $1.35M
Ending Cash Balance $26.95M $47.45M $35.73M $28.87M $28.87M
Net Change in Cash -$20.50M $11.73M $6.86M $515,000.00 -$7.17M
Beginning Cash Balance $47.45M $35.73M $28.87M $28.36M $36.04M
Free Cash Flow -$66.70M -$60.59M -$67.23M -$213.66M -$65.22M

Discussion

No comments yet — be the first to weigh in on CLDX.

Sign in to join the discussion.

Scroll to Top